Edgewise Therapeutics reported new data from an ongoing Phase II trial of its cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy (HCM) on 2 April that it contends could improve upon the current standard of care with cardiac myosin inhibitors (CMIs) such as Bristol Myers Squibb’s Camzyos (mavacamten). But the company’s share price declined sharply during the day, partly due to concerns about incidences of atrial fibrillation (AF) in the study.
Key Takeaways
- Edgewise’s EDG-7500, a cardiac sarcomere modulator, continued to show efficacy and safety edges in hypertrophic cardiomyopathy compared to the cardiac myosin inhibitor class.
- EDG-7500 demonstrated an ability to improve left ventricular outflow tract gradient in new Phase II data without corresponding decreases in left ventricular ejection fraction
Analysts called the drug’s efficacy data from part B of the Phase II open-label CIRRUS-HCM study in patients with both obstructive and non-obstructive HCM impressive and said investors’ apparent concerns about AF episodes were overdone
